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Abstract
Objective To determine the relative sufficiency of paired as-
pirates of posterior uveal melanomas obtained by FNAB for
cytopathology and GEP, and their prognostic significance for
predicting death from metastasis.
Methods Prospective non-randomized IRB-approved single-
center longitudinal clinical study of 159 patients with posteri-
or uveal melanoma sampled by FNAB in at least two tumor
sites between 09/2007 and 12/2010. Cases were analyzed with
regard to sufficiency of the obtained aspirates for
cytopathologic classification and GEP classification. Statisti-
cal strength of associations between variables and GEP class
was computed using Chi-square test. Cumulative actuarial
survival curves of subgroups of these patients based on their
cytopathologic versus GEP-assigned categories were comput-
ed by the Kaplan–Meier method. The endpoint for this sur-
vival analysis was death from metastatic uveal melanoma.
Results FNAB aspirates were insufficient for cytopathologic
classification in 34 of 159 cases (21.9 %). In contrast, FNAB
aspirates were insufficient for GEP classification in only one
of 159 cases (0.6 %). This difference is statistically significant
(P <0.001). Six of 34 tumors (17.6 %) that yielded an insuf-
ficient aspirate for cytopathologic diagnosis were categorized
as GEP class 2, while 43 of 125 tumors (34.7 %) that yielded a
sufficient aspirate for cytopathologic diagnosis were catego-
rized as GEP class 2. To date, 14 of the 49 patients with a GEP
class 2 tumor (28.6 %) but only five of the 109 patients with a
GEP class 1 tumor (5.6 %) have developed metastasis. Fifteen
of 125 patients (12 %) whose tumors yielded sufficient aspi-
rates for cytopathologic classification but only four of 34
patients (11.8 %) whose tumors yielded insufficient aspirates
for cytopathologic classification developed metastasis. The
median post-biopsy follow-up time for surviving patients in
this series was 32.5 months. Cumulative actuarial 5-year
probability of death from metastasis 14.1 % for those with
an insufficient aspirate for cytopathologic classification versus
22.4 % for those with a sufficient aspirate for cytopathologic
classification (log rank P=0.68). In contrast, the cumulative
actuarial 5-year probability of metastatic death was 8.0 % for
those with an insufficient/unsatisfactory aspirate for GEP
classification or GEP class 1 tumor, versus 45.0 % for those
with a GEP class 2 tumor (log rank P=0.005).
Conclusion This study confirmed that GEP classification of
posterior uveal melanoma cells obtained by FNAB is feasible
in almost all cases, including most in which FNAB yields an
insufficient aspirate for cytodiagnosis. The study also con-
firmed that GEP classification is substantially better than
cytologic classification for predicting subsequent metastasis
and metastatic death.
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Introduction
While ophthalmologists commonly regard primary uveal mel-
anoma as a purely ophthalmic disorder, the reality is that this
condition is a systemic disease that conveys to the affected
person a substantial risk of metastasis and metastatic death.
Although multiple clinical [1] and histopathological [2] fea-
tures of these tumors have been shown to be prognostic of an
affected person’s relative risk of developing metastasis, none
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of them individually or in combination has proven to be
particularly robust for identifying which patients in a group
will versus will not develop metastasis [1, 3–5]. In recent
years, certain chromosomal aberrations (most notably chro-
mosome 3 monosomy) [6, 7] and the gene expression profile
(GEP) [8–10] of uveal melanoma cells have been shown to be
far superior to clinical and histopathologic prognostic factors
for classifying an individual patient’s metastatic risk. Prelim-
inary reports of both chromosomal and transcriptional prog-
nostic factors for metastasis and metastatic death were based
largely on tumor specimens obtained post-enucleation. Be-
cause most uveal melanomas are managed today by locally
destructive tumor therapies and not by enucleation, an alter-
native method of procuring sufficient and representative spec-
imens of these tumors for chromosomal and/or transcriptional
testing must be employed in most cases. Fortunately, fine
needle aspiration biopsy (FNAB) has proven to be an effective
method for obtaining such tumor specimens, at least from
tumors classified by size as medium size or larger [10, 11].
According to published peer-reviewed data, primary uveal
melanomas evaluated by GEP cluster into two distinct sub-
groups [9]. GEP class 1 tumors are low grade melanomas that
are associated with low metastatic risk, while GEP class 2
tumors are high grade melanomas that are associated with
high metastatic risk. When GEP classification has been stud-
ied in head to head comparison with chromosomal testing by
various methods, GEP classification proved superior to chro-
mosomal classification for predicting metastatic risk.
This study was conducted with the purpose of determining
the relative sufficiency of paired aspirates of posterior uveal
melanomas obtained by fine needle aspiration biopsy (FNAB)
for cytopathologic classification and gene expression profile
(GEP) classification, and to determine the relative prognostic
significance of these different classifications for predicting
subsequent patient death from metastasis.
Methods
Our study was a prospective, non-randomized, IRB-approved,
single-center longitudinal clinical study of 159 patients with
primary posterior uveal melanoma sampled by FNAB be-
tween September 2007 and December 2010. All tumors in
this series were sampled in at least two separate sites, andmost
were sampled in four separate sites using previously published
FNAB techniques [11, 12]. The first and (when available)
third aspirates were suspended into a 50:50 mixture of bal-
anced salt solution and absolute alcohol, and submitted to our
pathology laboratory for cytopathologic processing and anal-
ysis [13]. The secondary and (when available) fourth aspirates
were flushed into a transport vial containing buffered tissue
culture medium, snap frozen on dry ice, and submitted to the
Harbour laboratory (Department of Ophthalmology and
Visual Sciences, Washington University, St. Louis, Missouri)
(n =134 cases, 81.3 %) or the Castle Biosciences, Inc., refer-
ence laboratory (Phoenix, Arizona) (n =25 cases, 18.7 %) for
gene expression profiling and GEP classification. GEP testing
on all cases in this series was performed using a previously
described PCR-based 15-gene assay comprising 12 discrimi-
nating genes and three endogenous control genes [10].
All patient data was retrieved, and all cases were analyzed
with regard to sufficiency of the obtained aspirates for
cytopathologic classification and GEP classification. Aspi-
rates were classified cytologicaly as insufficient for
cytopathologic diagnosis, melanocytic nevus, borderline
melanocytic tumor, spindle cell melanoma, mixed cell mela-
noma, unspecified uveal melanoma, epithelioid melanoma, or
necrotic melanoma. Aspirates were categorized by GEP as
class 1, class 2, or failed (GEP testing was unable to identify
all of the control genes after multiple amplifications).
Cumulative actuarial survival curves of subgroups of these
patients based on their cytopathologic versus GEP-assigned
categories were computed by the Kaplan–Meier method. The
endpoint of this survival analysis was death from metastatic
uveal melanoma. Significance of differences between the
curves was evaluated using the log rank test. Statistical
strength of associations between the studied clinical variables
and GEP class of the tumor was evaluated using cross-table
analysis with computation of the chi-squared statistic. An
alpha level of 0.05 was selected as the cutoff value for
assigning statistical significance of differences identified by
this analysis. All statistical analyses were performed using
Statistical Package for the Social Sciences (SPSS) version
11.1 for Windows.
Results
Our study group consisted of 159 patients whose ages ranged
from 17 to 87 years, with a median age of 60.6 years and mean
age of 60.9 years. There was no correlation between patient
age and GEP classification of the tumor (P=0.137). The
tumors studied had basal diameters that ranged from 4.5 to
22 mm (median 12 mm, mean=12mm), and thicknesses from
Table 1 Largest basal diameter versus GEP classification of 158 patients
with a melanocytic lesion sampled by FNAB
Crosstabs GEP class of tumor
Largest basal diameter (LBD) Class 1 [n (%)] Class 2 [n (%)]
Small (LDB≤10 mm) 47 (83.9 %) 9 (16.1 %)
Medium (LDB 10 mm<LDB≤
15 mm)
47 (63.5 %) 27 (36.5 %)
Large (LBD>15 mm) 15 (53.6 %) 13 (46.4 %)
P=0.007
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1.7 to 16 mm (median 5.4 mm, mean=5.8 mm). Tumors were
located anywhere from 0 to 23 mm from the disc (median
5.0=mm, mean=5.7 mm) and from 0 to 21 mm from the
fovea (median=4.5, mean=5.7 mm). The correlation between
largest basal diameter and GEP classification of the
melanocytic tumors studied is revealed in Table 1. One hun-
dred and fourteen patients (71.7 %) presented tumors that
were exclusively choroidal, and 45 patients presented ciliary
body involvement. The correlation between tumor involve-
ment (i.e., ciliary body involvement) and GEP classification
of the melanocytic tumors studied is revealed in Table 2.
FNAB yielded an insufficient aspirate for cytopathologic
classification in 34 of the 159 cases (21.4 %). In contrast, the
FNAB aspirates were insufficient (or unsatisfactory) for GEP
classification in only one of the 159 cases (0.6 %). This
difference is highly statistically significant (P <0.001).In
cases of sufficient aspirate for cytological diagnosis, one was
classified as a melanocytic nevus (0.6 %), ten were classified
as a borderline melanocytic tumor (6.3 %), 37 were spindle
cell melanoma (23.3 %), 34 were mixed cell melanoma
(21.4 %), eight were unspecified melanomas (5.0 %), and 35
were epithelioid cell or necrotic melanoma (22 %). The tumor
in the 158 successful cases was categorized as GEP class 1 in
109 (69.0 %%) and GEP class 2 in 49 (31.0 %) (Table 3).
Six of the 34 cases (17.6 %) with an insufficient aspirate
for cytopathologic classification proved to be Class 2 tumors
by GEP. Four of these six patients have died of choroidal
melanoma metastasis to date, and the other two have been
seen in recent clinical follow-up. Both patients remain
healthy and are metastasis-free. In contrast, 43 of the 125
cases (34.7 %) that yielded a sufficient FNAB aspirate for
cytopathologic classification proved to be GEP Class 2
tumors (Table 4).
Through available follow-up, 14 of the 49 patients (22.4%)
with a GEP class 2 tumor but only five of the 109 patients
(1.8 %) with a GEP class 1 tumor have developed metastasis
from their uveal melanoma (Table 5). In contrast, 15 of the
125 patients (12 %) with a sufficient aspirate for
cytopathologic classification versus four of the 34 cases
(11.8 %) with an insufficient aspirate for cytopathologic clas-
sification developed metastasis. The median post-FNAB
follow-up time among surviving patients in the entire group
was 56.4 months (±1.4 months) (95 % CI 53.5–59.2). The
median post-FNAB follow-up time of patients with a GEP
class 1 tumor was 60.6 months (±1.1 months) (95 % CI 58.3–
62.8). Meanwhile, median post-FNAB follow-up time of pa-
tients with a GEP class 2 tumor was 45.3 months
(±3.1 months) (95 % CI 39.3–51.4). The cumulative 5-year
mortality rate frommetastasis was 14.1% for the patients with
an insufficient aspirate for cytopathologic classification, ver-
sus 22.4 % for the patients with a sufficient aspirate for
cytopathologic classification (log rank P=0.68) (Fig. 1). In
contrast, the 5-year mortality rate from metastasis was 8.0 %
for the patients with insufficient aspirates for GEP or a GEP
class 1 tumor, versus 45.0 % for the patients with a GEP class
2 tumor (log rank P=0.005) (Fig. 2).
Table 2 Tumor location versus GEP classification of 158 patients with
melanocytic lesions sampled by FNAB
Crosstabs GEP class of tumor
Tumor location (ciliary body
involvement)
Class 1 [n (%)] Class 2 [n (%)]
Exclusively choroidal 87 (77.0 %) 26 (23.0 %)
Involving cilicary body 22 (48.9 %) 23 (51.1 %)
P=0.001
Table 3 Cytologic diagnosis
versus GEP class of 159 patients
submitted to fine needle aspira-
tion biopsy for cytologic and GEP
classification
P=0.034
Cytologic diagnosis Gene expression profile classification
Failed N (%) Class 1 [n (%)] Class 2 [n (%)]
Insufficient aspirate 28 (82.4 %) 6 (17.6 %)
Melanocytic nevus 1 (100 %)
Borderline melanocytic tumor 1 (10 %) 7 (70 %) 2 (20.0 %)
Spindle cell melanoma 27 (73.0 %) 10 (27.0 %)
Mixed cell melanoma 19 (55.9 %) 15 (44.1 %)
Unspecified melanoma 3 (37.5 %) 5 (62.5 %)
Epitheliod or necrotic melanoma 24 (68.6 %) 11 (31.4 %)
Total 1 (0.6 %) 109 (68.6 %) 49 (30.8 %)
Table 4 Sufficiency of aspirates for cytologic diagnosis versus GEP
classification of 158 patients with a melanocytic lesion sampled by
FNAB
Crosstabs GEP class of tumor
Sufficiency of aspirate for cytology Class 1 [n (%)] Class 2 [n (%)]
Insufficient for diagnosis 28 (82.4 %) 6 (17.6 %)
Sufficient for diagnosis 81 (65.3 %) 43 (34.7 %)
P=0.057
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Discussion
Recognizing the substantial potential for primary uveal mela-
nomas to metastasize and kill the affected host (regardless of
the method of primary treatment and the apparent local effec-
tiveness of that intervention), ophthalmologists and medical
oncologists have long desired a clinically useful method of
testing patients with this tumor that (1) has a high probability
of classification success in all patients tested, and (2) distin-
guishes reliably between those at high versus low risk of
developing metastasis. Gene expression profiling of the cells
of the primary intraocular tumor obtained by FNAB seems to
fulfill most of the desires [14, 15].
Because the clinical and cytologic prognostic factors for
survival of uveal melanoma patients have been extensively
discussed [1, 13, 16, 17], we described these findings in our
patient population and attempted to correlate them with GEP.
However, our study group is different than most series be-
cause it contains substantially more patients with small tumors
(largest basal diameter ≤3.5 mm) than other reported studies
[18, 19]. This is also reflected by the substantially lower
percentage of patients with a Class 2 tumor in our series [8].
Largest basal diameter of the studied tumors presented a
significant correlation with GEP classification. Smaller tu-
mors were much more likely to be GEP class 1; however, in
the larger tumors the difference in distribution between class 1
and class 2 tumors by GEP was not as distinguishable. Once
again, this result may be due to our sample being composed of
smaller tumors, and perhaps a larger sample size would show
a more significant trend in the distribution GEP class among
the medium and larger tumors.
Tumors involving the ciliary body have been known to
have a worse survival prognosis [4]. In our series, tumors that
were exclusively choroidal were much more likely to be class
1 and consequently carry a better survival prognosis, and there
was a trend towards tumors with ciliary body involvement
being more likely class 2. This correlation, although statisti-
cally significant, probably needs a larger sample size to reveal
a more distinctive distribution of tumors involving the ciliary
body classified by GEP as class 1 or class 2.
The yield of FNAB is an important topic to be considered.
Many authors have pointed out the limited specimen yield of
FNAB using smaller gauge needles (25- and 27-G) as a
limitation for the widespread use of FNAB. Conversely,
FNAB yield for cytology has been reported to be lower among
smaller thinner tumors [20]. Although our group has shown
that an insufficient aspirate for cytologic diagnosis may be a
meaningful result, especially among smaller tumors [21], it is
curious to see that GEP testing seems to be feasible in almost
all cases, even in very minute specimens, and was able to
reveal that a number of cases of insufficient aspirates or
diagnosed as nevi proved to be class 2 tumors. However,
contrary to our previous experience, the survival of patients
whose FNAB yielded an insufficient aspirate for cytoilogy
was not significantly different from the group whose FNAB
yielded a sufficient aspirate. Reviewing these cases and the
Table 5 Metastatic disease status versus GEP classification of 158
patients with a melanocytic lesion sampled by FNAB
Crosstabs GEP class of tumor
Metastatic disease status Class 1 [n (%)] Class 2 [n (%)]
No metastasis detected 104 (95.4 %) 35 (71.4 %)
Metastasis identified 5 (4.6 %) 14 (28.6 %)
P<0.001
Fig. 1 Kaplan–Meier survival curves of 159 patients divided into sub-
groups according to their sufficiency of aspirate for cytologic diagnosis
(insufficient aspirate=34 patients and sufficient aspirate=125 patients).
(p =0.68)
Fig. 2 Kaplan–Meier survival curves of 158 patients divided in sub-
groups according to their GEP classification (GEP class 1 = 109 patients
and GEP class 2 = 49 patients). (p =0.005)
134 Graefes Arch Clin Exp Ophthalmol (2014) 252:131–135
cytologic assessment at the time, it was brought to our atten-
tion that these studies were performed by a new pathology
group, and probably because of their lack of experience with
minute specimens, we speculate that the assessment of an
insufficient aspirate was made in a substantially larger number
of cases.
Furthermore, our study has shown a definite trend in corre-
lation between insufficiency of aspirates and class 1 tumors. An
association between absence of epithelioid cells and GEP class
1 tumors cannot be established at this point. Again, definitive
correlations may not be present due to our sample size.
This study confirmed that GEP classification of frozen
posterior uveal melanoma cells obtained by FNAB is feasible
in almost all cases, including most in which FNAB yields an
insufficient aspirate for cytopathologic diagnosis. The study
also confirmed that GEP classification is substantially better
than cytopathologic classification for predicting subsequent
metastasis and metastatic death.
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